Zoetis Inc. $ZTS Shares Sold by Blackhill Capital Inc.

Blackhill Capital Inc. cut its position in Zoetis Inc. (NYSE:ZTS) by 27.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,899 shares of the company’s stock after selling 35,400 shares during the quarter. Zoetis makes up 0.6% of Blackhill Capital Inc.’s investment portfolio, making the stock its 14th biggest holding. Blackhill Capital Inc.’s holdings in Zoetis were worth $12,066,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis during the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $32,000. Finally, Elyxium Wealth LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $32,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on ZTS shares. UBS Group decreased their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Citigroup decreased their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $133.92.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $79.51 on Friday. The company has a market cap of $33.33 billion, a price-to-earnings ratio of 13.19, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75. The stock has a 50 day simple moving average of $96.94 and a 200-day simple moving average of $114.22. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $167.38. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.